![](/images/graphics-bg.png)
Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
Joint Authors
Yan, Weiqi
Liu, Zhuojun
Liu, Jia
Xia, Yuanshi
Hu, Kai
Yu, Jian
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-10-01
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies.
However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies.
Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies.
Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials.
However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage.
In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), Hodgkin’s lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML).
Moreover, we will review the disadvantages of CAR-T cell therapy and propose several comprehensive recommendations which might guide its development.
American Psychological Association (APA)
Yan, Weiqi& Liu, Zhuojun& Liu, Jia& Xia, Yuanshi& Hu, Kai& Yu, Jian. 2020. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. BioMed Research International،Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1133800
Modern Language Association (MLA)
Yan, Weiqi…[et al.]. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. BioMed Research International No. 2020 (2020), pp.1-9.
https://search.emarefa.net/detail/BIM-1133800
American Medical Association (AMA)
Yan, Weiqi& Liu, Zhuojun& Liu, Jia& Xia, Yuanshi& Hu, Kai& Yu, Jian. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1133800
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1133800